ESH MM 2018 | How do we define a ‘cure’ in myeloma?

Annemiek Broyl

How to we define a ‘cure’ in multiple myeloma (MM)? We spoke to Annemiek Broyl, MD, PhD, of Erasmus Medical Center and University, Rotterdam, Netherlands, about this important and interesting topic, as well as the role of measurable residual disease (MRD) in this definition, at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video